Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech’s First Quarter Solid, Avastin Slow

This article was originally published in The Pink Sheet Daily

Executive Summary

Breast-cancer push not yet in full swing, company says.

You may also be interested in...



Rituxan For Lupus Misses Primary, Secondary Endpoints

Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.

Rituxan For Lupus Misses Primary, Secondary Endpoints

Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.

Avastin Misses Overall-survival Endpoint In Lung Cancer

Analysts expect minimal damage to sales as a result of AVAiL data.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel